Emerging markets offer significant untapped sales potential for biopharma companies, but bringing a new product to these markets can be complicated, costly and time consuming. In this paper Evangelos Tryfonidis, Vice President of Business Development, Emerging Markets outlines the obstacles small and mid-sized biopharma companies face when entering emerging markets, the benefits and risks of different market access strategies, and how to choose an approach that delivers the most long term value to their business.

Author: Evangelos Tryfonidis, Vice President of Business Development, Emerging Markets